PGEN Precigen Inc

$PGEN just took out $8.00. The best part is we are moving higher before some of the biggest pieces of the story have even played out. Lots of runway left here

$PGEN Accelerated approval typically requires a drug to fill a critical, unaddressed medical space. Because Precigen's Papzimeos already secured approval, the FDA is signaling that Inovio might no longer qualify for an automated fast track

$PGEN how is this a 6 dollar stock again. my god dont you investors realize earnings are coming out in 2 weeks. revenues revenues revenues. im predicting now we are looking at 200 million revenues in the 3ed quarter

$PGEN Let’s see who thinks it goes up this week? I know who the fake bulls are now. Sell more calls I’ll take those too, go ahead, I’m serious. This is gonna be fun.

$PGEN I want to be careful saying this because there are real patients desperately waiting for effective treatment, and that matters more than any stock price. But from an investor’s perspective, we are set up beautifully right now. The catalysts are lining up, the story is getting stronger, and the market is finally starting to recognize what PGEN has been building. The only thing I see looming on the horizon is October 30 with INO. That could be the one thorn in an otherwise pretty damn beautiful setup. Hopefully, the science ultimately wins for the patients who need it and as shareholders, we’ll see where the cards fall

$PGEN a good reminder to look for names where improving fundamentals outweigh macro concerns

$PGEN Added multiple today. Those that want to sell, please exit and I’ll take your shares.

$PGEN For those who understand the enormous significance of this morning’s PR, I bet we have some updated price targets before November and with 1-2mos after November. Before November, I would not be surprised to see several get in line with $20 or so. After November, assuming the absolute most positive info, PT ranges from $25-$35. That’s just my opinion if all is highly positive.

$PGEN From my good friend Gemini Earlier, Frequent FDA Interaction: The company gains enhanced access to FDA interactions during development. This reduces regulatory uncertainty and helps align trial designs earlier, cutting years off development cycles. Immediate Pipeline Boost The most direct immediate beneficiary is PRGN-2009, currently in Phase 2 trials for HPV-associated oropharyngeal squamous cell carcinoma and recurrent/metastatic cervical cancer. Strategic Bottom Line For a biotech managing capital efficiency and advancing a broad pipeline, this designation serves as a force multiplier. It shifts the market perception of Precigen from a company with single, isolated drug shots on goal to a validated plug-and-play platform company capable of systematically outputting regulatory-cleared therapeutics faster and cheaper.

$PGEN holy shit…. 2nd company ever to receive this from my knowledge. 2009 data must be really interesting

$PGEN XBI is down 3.5% Looks like INO's potential market entrance is dragging the entire sector down! /s

$PGEN FDA explicitly included a preliminary conclusion stating that Inovio had not submitted adequate information to justify eligibility for the accelerated approval pathway.

$PGEN The harder it gets pushed, the more impressive it is that it keeps getting back up.

$PGEN this company has executed perfectly over the last year. It’s so exciting to know we are just getting started. To the mother fucking moon we go!

$PGEN I'm betting Helen and the PR team's 2.5 month silence will be broken on Monday with at least the official date for the Q3 call.

$PGEN This isn’t a knock on Precigen or their product, but honestly, I don’t think I’d want to be an investor here right now. If INO-3107 gets FDA approval, I think PGEN could take a pretty serious hit, potentially 30–50%, simply because the market would suddenly have another approved treatment for RRP. Why would you take that risk with the FDA decision coming this close? Personally, I’d rather sell now and, if you really love PGEN, come back after the FDA makes its decision on INO-3107. I know some of you are going to hate hearing that, but that’s honestly how I see it. Attack me all you want. We’re all going to find out very soon.

$PGEN many biotechnology companies had huge moves today only to pullback a bit near the close as the indexes pulled back. Still, beautiful breakout on huge volume. IMHO Kirk is just waiting for the right offer. He is greedy and won't give pgen away. Guessing he wants at least 20. Im good with that.

$PGEN Finally it ended above 8 dollars. Will be interesting to see what happens tomorrow.

$PGEN $INO Probably the most on the dot coverage I've seen in a while. "Papzimeos has first mover advantage in market adoption by more than four quarters, while INO-3107 has a non-differentiating profile" I've been beating this drum for a while. Both treatments (Papzimeos and INO-3107) are pretty much neck and neck when it comes to patient results when you account for trial construction differences. The huge differentiator becomes who's there first to market and how the team capitalizes on the opportunities granted to them. I know which horse I have my money on.

$PGEN I sold a few yesterday, just to down size my risk. I’m keeping the bulk. The competing treatment with a PFUDA date of 10/30 needs special equipment lol Pgen is easy if use and has the adenovirus platform, it’s frankly a more usable better treatment, regardless of what happens and it’s currently the only treatment.